ποΈ Risk-Based Cancer Screening · Apgujeong Hana Clinic
Cancer Screening Program Seoul
English-friendly cancer screening in Gangnam—matching established organ-specific tests to age, sex, smoking, family history, infection risk and previous findings, with preparation support and a clear pathway for abnormal results.
β
Personal cancer-risk review
β
Organ-specific screening
β
English follow-up planning
π§¬
Risk Assessment
Family, hereditary, infection, smoking and previous-lesion risk.
π
Evidence-Based Test
Select an established screening method for the correct organ.
π
Preparation Guidance
Fasting, bowel preparation, imaging and medicine instructions.
β‘οΈ
Abnormal-Result Pathway
Diagnostic confirmation, biopsy, referral or surveillance.
β
English Cancer Screening Support
β
Organ-Specific Test Selection
β
Clear Diagnostic Follow-Up
β
Apgujeong · Gangnam
What Is Cancer Screening?
Screening looks for selected cancers before symptoms appear.
Cancer screening is offered to people who do not have symptoms of the cancer being screened for. The goal is to find a cancer earlier, or in some programs to detect and treat precancerous changes before cancer develops.
A screening test is not usually a final diagnosis. If the result is abnormal, additional diagnostic testing may be required. Depending on the organ, this may involve focused imaging, endoscopy, biopsy or specialist assessment.
Screening recommendations differ because each cancer has different biology, risk factors and evidence. A test that is useful for one cancer cannot automatically be applied to another.
β³
Before Symptoms
Screening is designed for eligible people without relevant warning symptoms.
π―
Organ Specific
Mammography, HPV testing, stool testing and low-dose CT answer different questions.
π¬
Confirmation May Be Needed
Abnormal screening often requires diagnostic testing or biopsy.
βοΈ
Benefits & Harms
The decision should consider false results, overdiagnosis and procedure risks.
Who Needs A Personalised Plan?
Risk can change the test, age of starting and frequency.
π§¬
Strong Family History
Multiple relatives, young-age cancer or related cancer patterns may justify genetics or specialist review.
π¬
Smoking History
Current and former heavy smokers may qualify for lung screening under specific criteria.
π¦
Chronic Infection Risk
HPV, hepatitis B, hepatitis C and H. pylori can affect prevention or screening pathways.
π
Previous Abnormal Result
Polyps, dysplasia, nodules or abnormal cytology require surveillance rather than routine screening.
π§¬
Hereditary Syndrome
BRCA-related risk, Lynch syndrome or other inherited conditions require specialist protocols.
π«
Liver High-Risk Group
Chronic hepatitis or cirrhosis can require repeated liver surveillance.
π
Previous Cancer Treatment
Survivorship surveillance follows the original cancer and treatment plan.
π
Different National Histories
International patients may need overseas and Korean records reconciled into one plan.
Organ-Specific Screening Pathways
Each cancer requires the right screening method for the right risk group.
π½οΈ
Stomach Cancer Screening
Korea's national program includes adults aged 40 and over every two years using upper-GI imaging or gastrointestinal endoscopy. Personal risk and symptoms may change the pathway.
Gastroscopy / UGI
π«
Liver Cancer Surveillance
Screening is intended for high-risk groups rather than all adults. Korea's national program combines abdominal ultrasound and serum AFP every six months for defined high-risk adults aged 40 and over.
Ultrasound + AFP
π§»
Colorectal Cancer Screening
Options may include stool testing or direct visualisation. An abnormal stool test generally requires colonoscopy, while colonoscopy can also remove precancerous polyps.
FIT / FOBT / Colonoscopy
π
Breast Cancer Screening
Mammography is the established screening test for average-risk women in the relevant age group. Dense breasts, family history or genetic risk may require additional discussion.
Mammography
πΈ
Cervical Cancer Screening
HPV testing and cervical cytology can detect high-risk infection or abnormal cells before invasive cancer develops. The method and interval depend on age and prior results.
HPV Test / Pap Test
π«
Lung Cancer Screening
Low-dose CT is for selected adults with substantial smoking exposure. It is not recommended as a routine chest scan for every nonsmoker.
Low-Dose CT
π¨
Prostate Cancer Discussion
PSA screening requires shared decision-making because false positives, biopsy and overdiagnosis are possible. It is not part of Korea's six-cancer national screening list.
PSA Discussion
π§¬
Hereditary Cancer Assessment
Genetic testing is most useful after risk assessment and counselling. Broad testing without interpreting family history can produce uncertain findings.
Risk Review / Genetics
π¬
Diagnostic Follow-Up
Symptoms, a palpable lump, bleeding or an abnormal screening result require diagnostic—not routine screening—assessment and may include biopsy.
Imaging / Endoscopy / Biopsy
Korea National Cancer Screening Context
Six cancer sites are included under Korea's national program.
The National Cancer Center lists stomach, liver, colorectal, breast, cervical and lung cancer screening pathways. Eligibility and cost depend on current NHIS or Medical Aid rules and authorised screening providers.
Cancer
Target
Frequency
National Program Method
Stomach
Adults 40+
Every 2 years
UGI imaging or gastrointestinal endoscopy with biopsy when indicated
Liver
High-risk adults 40+
Every 6 months
Abdominal ultrasound plus serum AFP
Colorectal
Adults 50+
Every year
FOBT first; colonoscopy with biopsy after an indicated result
Breast
Women 40+
Every 2 years
Mammography
Cervix
Women 20+
Every 2 years
Pap smear
Lung
High-risk adults 54–74
Every 2 years
Low-dose CT under the defined smoking-risk criteria
National-program eligibility and private clinic services are not the same
Confirm whether the clinic is an authorised provider for the relevant NHIS benefit, whether you are personally eligible and which tests are private or billed separately.
Your Cancer Screening Consultation
The plan begins with history—not a preselected tumour-marker panel.
π©Ί
Screening is useful only when it can lead to appropriate follow-up.
The doctor reviews whether the person is eligible, whether the test is likely to help and what diagnostic pathway will follow an abnormal result.
ποΈ
Age & Previous Screening
Review what was done, when, and whether the result was normal.
π§¬
Family History
Record the cancer type, relative and age at diagnosis.
π¬
Smoking Exposure
Current status, years smoked and packs per day guide lung-risk assessment.
π¦
Infection & Liver Risk
HPV, hepatitis, cirrhosis and H. pylori history may affect pathways.
π
Prior Abnormal Findings
Bring pathology, imaging, endoscopy and cytology reports.
π
Medicines & Procedure Risk
Blood thinners, pregnancy and chronic disease can affect preparation.
Screening Journey
From risk review to a completed follow-up pathway.
1
Assess Risk
Review age, sex, family history, smoking, infections and previous findings.
2
Select Tests
Choose established organ-specific screening methods and intervals.
3
Prepare
Follow fasting, bowel preparation, medicine, imaging or sedation guidance.
4
Complete Screening
Undergo the selected laboratory, imaging, endoscopic or cytology tests.
5
Close The Loop
Review results and complete diagnostic confirmation or future scheduling.
Preparation By Test Type
Different cancer-screening tests require different preparation.
π½οΈ
Gastroscopy
Fasting, medicine and sedation instructions must be followed exactly.
π§»
Colonoscopy
Bowel preparation quality directly affects whether the colon lining can be examined.
π©»
CT or Imaging
Pregnancy possibility, contrast allergy and kidney risk should be discussed.
π
Mammography
Bring prior breast images where possible and report symptoms or implants.
πΈ
Cervical Sampling
Timing, bleeding, pregnancy and prior cervical treatment may affect collection.
π©Έ
Blood Tests
Most tumour-marker tests do not require fasting, but combined health checks may.
π
Medicines
Ask before changing blood thinners, diabetes medicine or other prescribed treatment.
π
Previous Reports
Comparison can prevent duplication and clarify whether screening or surveillance is due.
After An Abnormal Screening Result
An abnormal result begins a diagnostic pathway—it does not confirm cancer.
π‘
Screening Finding
A mammogram, stool test, cytology, CT, endoscopy or laboratory result is abnormal.
π
Diagnostic Clarification
Focused imaging, repeat testing, colonoscopy, gastroscopy or specialist assessment may follow.
π¬
Biopsy When Indicated
Pathology examines tissue when a lesion requires definitive classification.
π
Plan & Follow-Up
The outcome may be reassurance, surveillance, treatment or referral to cancer care.
Screening only saves lives when abnormal results receive timely follow-up
Before testing, confirm who will communicate the result, how long it may take and where diagnostic procedures will be arranged if needed.
Tumour Markers & Multi-Cancer Blood Tests
Convenient blood testing is not the same as proven population screening.
β Appropriate Uses May Include
β
Selected diagnosis or monitoring after a clinical concern is identified.
β
Surveillance in a defined high-risk group, such as AFP with liver ultrasound.
β
Monitoring some previously diagnosed cancers under specialist guidance.
β
Research or a clearly explained shared-decision context.
β
Interpretation alongside imaging, examination and medical history.
β οΈ Important Limitations
!
A normal tumour marker cannot rule out cancer.
!
Benign conditions can produce abnormal marker results.
!
Broad panels can create false alarms and unnecessary procedures.
!
Multi-cancer detection tests have not replaced established screening.
!
A positive blood signal may not identify the cancer's location clearly.
Do not replace mammography, cervical testing, stool testing, colonoscopy or low-dose CT with a generic cancer blood panel
Established screening pathways have organ-specific evidence and follow-up protocols. Newer blood tests require careful interpretation and may still be under evaluation.
Benefits & Harms
Shared decision-making should include both sides.
β Potential Benefits
β
Detect selected cancers at an earlier, more treatable stage.
β
Reduce cancer mortality when an effective program is used correctly.
β
Prevent some cancers by identifying and treating precancerous change.
β
Establish an organised follow-up schedule.
β
Identify high-risk patients who need specialist surveillance.
β οΈ Potential Harms
!
False-positive results, anxiety and additional testing.
!
False-negative results and incorrect reassurance.
!
Overdiagnosis and treatment of cancers that may never have caused harm.
!
Radiation, contrast, bleeding, infection or perforation from procedures.
!
Incidental findings that create further investigations.
Screening Is Not For Symptoms
Warning symptoms require diagnostic evaluation without waiting for a screening interval.
π©Έ
Unexplained Bleeding
Blood in stool or urine, black stool, coughing blood or unexplained vaginal bleeding requires assessment.
π
Unintentional Weight Loss
Persistent unexplained weight loss should not be managed as routine screening.
π§±
New Lump or Swelling
A new breast, neck, testicular or other lump requires diagnostic examination.
π½οΈ
Persistent GI Symptoms
Difficulty swallowing, vomiting, changing bowel habits or persistent abdominal pain needs targeted care.
π«
Persistent Cough
Cough, hoarseness or breathlessness that persists or worsens requires evaluation.
π‘οΈ
Unexplained Systemic Symptoms
Persistent fever, night sweats or severe fatigue may require diagnostic testing.
π§
Neurological Change
New weakness, seizure, confusion, severe headache or vision change requires prompt assessment.
π
Rapid Change
Any rapidly worsening or concerning symptom should be assessed promptly.
Apgujeong, Gangnam
Cancer screening planning and follow-up in English.
Apgujeong Hana Clinic provides risk review, screening coordination, preparation guidance, result explanation and diagnostic follow-up planning for expats, residents and international patients in Seoul.
π
328 Apgujeong-ro, Gangnam-gu, Seoul, KFC Building 3F
π
Monday–Friday 09:00–19:00
ποΈ
Saturday 09:00–13:00
π
02) 3443-7550
ποΈ
Risk-Based Screening Review
The program matches established tests to personal risk and keeps a clear pathway from screening result to diagnostic confirmation when needed.
FAQ
Cancer screening questions, answered.
Eligibility, interval, preparation, coverage and test availability depend on the organ, current guidance and personal risk.
A cancer screening program checks selected people for certain cancers or precancerous changes before symptoms appear. Tests are chosen by age, sex, smoking, family history, infection risk and previous results.
Usually not. An abnormal screening result means that diagnostic imaging, endoscopy, biopsy or another test may be needed before cancer is confirmed or excluded.
Established pathways include breast, cervical, colorectal and lung screening for eligible groups. Korea's national program also includes stomach and high-risk liver screening. Other cancers need individual discussion.
No established single blood test screens reliably for every cancer. Tumour-marker and multi-cancer blood tests have important limitations and do not replace recommended organ-specific screening.
Yes, when clinically appropriate and available. Gastroscopy is relevant to stomach screening in Korea, and colonoscopy may be used for colorectal screening or after an abnormal stool test. Preparation and sedation rules apply.
Earlier or more intensive screening may be appropriate with a strong family history, hereditary syndrome, previous precancerous lesion, inflammatory bowel disease, chronic hepatitis, cirrhosis or another high-risk condition.
The next step depends on the test. It may include repeat testing, diagnostic imaging, specialist consultation, endoscopy or biopsy. A clear follow-up pathway is essential.
Possible harms include false positives, false negatives, overdiagnosis, anxiety, radiation, contrast reactions, bleeding, perforation and unnecessary follow-up procedures.
NHIS provides eligible cancer screenings through authorised institutions under national criteria. Private packages, additional tests and out-of-program services may have separate costs.
Yes. Apgujeong Hana Clinic provides English booking support, risk review, preparation guidance, result explanation and follow-up planning for international patients in Seoul.
Related Health Screening Programs
Continue with the screening pathway that fits your needs.
English Cancer Screening
Choose the right cancer test—and complete the right follow-up.
Contact Apgujeong Hana Clinic to review age, family history, smoking, previous findings, Korean screening eligibility and appropriate next steps.